Endocyte, Inc. (NASDAQ:ECYT) – Research analysts at Wedbush decreased their Q1 2018 earnings per share estimates for Endocyte in a research report issued on Monday. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings of ($0.20) per share for the quarter, down from their previous estimate of ($0.17). Wedbush also issued estimates for Endocyte’s Q2 2018 earnings at ($0.24) EPS, Q3 2018 earnings at ($0.26) EPS, Q4 2018 earnings at ($0.28) EPS, FY2018 earnings at ($0.98) EPS, FY2019 earnings at ($0.91) EPS, FY2020 earnings at ($1.45) EPS and FY2021 earnings at ($1.04) EPS.
A number of other research firms also recently commented on ECYT. ValuEngine downgraded shares of Endocyte from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. Zacks Investment Research upgraded shares of Endocyte from a “sell” rating to a “hold” rating in a report on Friday, February 9th. Finally, Cowen upgraded shares of Endocyte from a “market perform” rating to an “outperform” rating in a report on Tuesday.
Endocyte (NASDAQ:ECYT) last released its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.02). Endocyte had a negative return on equity of 38.63% and a negative net margin of 78,662.86%. The company had revenue of $0.01 million for the quarter. During the same period in the previous year, the business posted ($0.26) EPS. The firm’s revenue was up .0% on a year-over-year basis.
In other Endocyte news, insider Philip S. Low sold 50,511 shares of the stock in a transaction dated Thursday, December 28th. The shares were sold at an average price of $4.41, for a total value of $222,753.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Christopher P. Leamon sold 23,231 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $5.04, for a total transaction of $117,084.24. Following the completion of the sale, the vice president now owns 150,579 shares of the company’s stock, valued at approximately $758,918.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 124,253 shares of company stock valued at $562,591. 14.86% of the stock is owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in the business. FMR LLC raised its holdings in Endocyte by 0.9% in the 2nd quarter. FMR LLC now owns 3,540,203 shares of the biopharmaceutical company’s stock valued at $5,310,000 after acquiring an additional 31,168 shares during the last quarter. Perceptive Advisors LLC acquired a new stake in Endocyte in the 4th quarter valued at about $6,213,000. BlackRock Inc. grew its stake in shares of Endocyte by 223.7% in the 4th quarter. BlackRock Inc. now owns 1,138,791 shares of the biopharmaceutical company’s stock valued at $4,875,000 after buying an additional 786,933 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Endocyte by 1,064.3% in the 2nd quarter. Goldman Sachs Group Inc. now owns 430,994 shares of the biopharmaceutical company’s stock valued at $646,000 after buying an additional 393,975 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of Endocyte by 42.0% in the 4th quarter. Renaissance Technologies LLC now owns 293,580 shares of the biopharmaceutical company’s stock valued at $1,257,000 after buying an additional 86,800 shares during the period. Institutional investors own 19.45% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Endocyte, Inc. (ECYT) to Post Q1 2018 Earnings of ($0.20) Per Share, Wedbush Forecasts” was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3230232/endocyte-inc-ecyt-to-post-q1-2018-earnings-of-0-20-per-share-wedbush-forecasts.html.
Endocyte Company Profile
Endocyte Inc (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), the Company’s second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company’s non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).
Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.